## RECOVERY

## Randomised Evaluation of COVID-19 Therapy Sample Form (v12.00 - 17/12/20)

## **Randomisation Program**

Call Freefone 0800 138 5451 to contact the RECOVERY team for URGENT problems using the Randomisation Program or for medical advice. All NON-URGENT queries should be emailed to recoverytrial@ndph.ox.ac.uk

	Section A: B
T	Date and time of r
Treating clinician A1. Name of treating clinician	
Patient details A2. Patient surname	
A2. Patient surname Patient forename	
A3. NHS number	
	Tick if not available
A4. What is the patient's date of birth?	01 v / January v / 2000 v
A5. What is the patient's sex? Inclusion criteria	<b></b>
A6. Has consent been taken in line with the protocol? If answer is No patient cannot be enrolled in the study	<b>v</b>
A7. Does the patient have proven or suspected SARS-CoV-	<b>v</b>
2 infection? If answer is No patient cannot be enrolled in the study	
A8. Does the patient have any medical history that might, in the opinion of the attending clinician, put the patient at significant risk if they were to participate in the trial?	<b>`</b>
A8B. Is the patient willing to receive convalescent plasma?	<b>`</b>
A9. COVID-19 symptom onset date:	<b>v</b> / <b>v</b> / <b>v</b>
A10. Date of hospitalisation:	• / • / •
A11. Does the patient require oxygen?	<b>~</b>
A12. Please select one of the following to describe the	
current level of ventilation support A12.1 Enter latest oxygen saturation measurement (%)	
A12.2 Enter latest CRP measurement since admission to hospital (mg/L)	Tick if not measured Tick if greater than limit of measurement
Enter 0 if below the limit of measurement A12.3 Enter latest creatinine measurement since	
admission to hospital (µmol/L) A12.4 Enter latest D-dimer measurement since admission	
to hospital (ng/mL) Enter 0 if below the limit of measurement	Tick if greater than limit of measurement
A12.5 Has the patient received a COVID-19 vaccine?	<b></b>
Does the patient have any CURRENT comorbidities or o A13.1 Diabetes	other medical problems or treatments?
A13.2 Heart disease	
A13.3 Chronic lung disease	
A13.4 Tuberculosis	
A13.5 HIV	
A13.6 Severe liver disease	
A13.7 Severe kidney impairment (eGFR<30 or on dialysis)	<b>`</b>
A13.8 Known long QT syndrome	<b>~</b>
A13.9 Current treatment with macrolide antibiotics which are to continue Macrolide antibiotics include clarithromycin, azithromycin and erythromycin	<b>``</b>
A13.10 Antiplatelet therapy Includes aspirin, clopidogrel, ticagrelor, prasugrel,	
dipyridamole A13.11 Previous adverse reaction to blood or blood	~
product transfusion Are the following treatments UNSUITABLE for the pa	
If you answer Yes it means you think this patient shou A14.3 Colchicine	Id NOT receive this drug.
A14B.1 Convalescent plasma	
A14B.2 Synthetic monoclonal antibodies (REGN10933+REGN10987)	<b></b>
A14C.1 Aspirin	<b>`</b>
Are the following treatments available? A15.3 Colchicine	<b>v</b>
A15B.1 Convalescent plasma	
A15B.2 Synthetic monoclonal antibodies	
(REGN10933+REGN10987)	
A15C.1 Aspirin Current medication	<b>`</b>
A16.1 Is the patient currently prescribed remdesivir?	~
A16.2 Is the patient currently prescribed systemic corticosteroids (dexamethasone, prednisolone, hydrocortisone, methylprednisolone)?	
Plesse do not include topical or inhaled treatments A16.4 Is the patient currently on warfarin or a direct oral anticoagulant?	<b>~</b>
Includes apixaban, rivaroxaban	
A16.5 What venous thromboembolism prophylaxis is the patient receiving: Stordard - usual for hospitalized patients (not increased due to COVID-19); Higher dose = treatment dose or increased prophysias due to COVID-19 Please sign off this form once complete	v
Surname:	
Forename:	
Professional email:	
	Continue